Electra Therapeutics, Inc.

CERT inactive

424B4 priced

Price $15.00 · 23,333,334 shares · Gross proceeds $350,000,010

Electra Therapeutics, Inc. has filed a final prospectus (424B4) for its initial public offering (IPO), detailing the terms of the offering. The company plans to raise capital by selling common stock at an initial public offering price of $15.00 per share, with underwriters including Jefferies LLC, TD Securities (USA) LLC, and Evercore Group L.L.C. The offering includes an option for underwriters to purchase additional shares, and the company expects proceeds of $325.5 million before expenses. The filing highlights risks related to market liquidity, price volatility, and the underwriters' discretionary market-making activities. The stock will be listed on Nasdaq under the symbol ETRA.

8-A12B effective

EFFECT effective

S-1/A amended

Price $15.00 · Range $14.00 to $16.00 · 21,666,667 shares

Electra Therapeutics, Inc. filed an S-1/A amendment to its IPO registration statement, reflecting updates to share structure, financial assumptions, and operational details. Key changes include a one-for-1.5002 reverse stock split, adjusted conversion of redeemable convertible preferred stock into 39,404,292 common shares, and finalized financial projections. The filing also clarifies assumptions around stock option exercises, underwriter options, and the impact of the offering on capitalization.

S-1 filed

Electra Therapeutics, Inc. is conducting an IPO with a focus on converting redeemable convertible preferred stock into common stock, implementing a reverse stock split, and detailing financial losses. The filing includes pro forma financial data assuming these conversions and a potential offering. The company remains unprofitable, with significant accumulated deficits and ongoing research and development expenses.

DRS/A amended

Electra Therapeutics, Inc. is preparing for its initial public offering (IPO) with underwriters Jefferies LLC and TD Securities (USA) LLC. The filing outlines key terms including the public offering price, underwriting discounts, and proceeds. The company has granted underwriters an option to purchase additional shares, and there are restrictions on stock sales by insiders for 180 days. The underwriters may engage in market-making activities, though they are not obligated to do so, and no assurances are given about the liquidity or future trading price of the stock. The shares are set to be listed on the Nasdaq Global Select Market under the symbol "ETRA."

DRS filed

Electra Therapeutics, Inc. is preparing for its initial public offering (IPO) with underwriters Jefferies LLC and TD Securities (USA) LLC. The filing outlines the underwriting terms, including the public offering price, underwriting discounts, and proceeds. Key details include a 180-day lock-up period restricting sales by insiders, potential stabilization activities by underwriters to influence stock price, and no guarantees of liquidity or favorable trading prices post-offering. The company has not previously had a public market for its stock, and the offering price will be determined through negotiations. The underwriters may adjust prices post-offering but will not alter the proceeds to the company. The stock is intended to be listed on Nasdaq under 'ETRA.'